IgE CH3 PEPTIDE VACCINE

• Main Authors: BROWN ALAN DANIEL, KJERRSTROM ANNE MARIA KRISTINA, DAVID CAMERON PRIDE, DAVID MICHAEL WYATT, DAVID PAUL GELBER, ROBERTS LEE RICHARD, LIN HOWARD JONES, BRIAN ROBERT CHAMPION, CHRISTY CLARE
• Format: Patent
• Language: English; Japanese
• Published: 08.09.2016
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders.SOLUTION: The antigenic IgE peptide is linked to the immunogenic carrier (VLP) via a linker. The immunogenic composition of the present invention comprises at least one adjuvant. The adjuvant is an immunostimulatory oligonucleotide, and more preferably a CpG oligonucleotide. The invention further relates to methods for producing these medicaments, methods for producing immunogenic compositions and pharmaceutical compositing thereof, and their use in medicine.SELECTED DRAWING: None 【課題】ＩｇＥ媒介性障害を予防、治療、または軽減するための、好ましくは免疫原性担体に連結された抗原性ＩｇＥペプチドを含む新規の免疫原の提供。【解決手段】抗原性ＩｇＥペプチドはリンカーを介して免疫原性担体（ＶＬＰ）に結合される。また対象免疫原性組成物は少なくとも１つのアジュバンドを含む。アジュバンドは、免疫賦活性オリゴヌクレオチド、より好ましくはＣｐＧオリゴヌクレオチドである。更に、これらの薬物、その免疫原性組成物および医薬組成物を製造するための方法、および医薬におけるこれらの使用。【選択図】なし